Infarct size reduction with the nucleoside transport inhibitor R-75231 in swine

American Journal of Physiology - Heart and Circulatory Physiology

Volumn 272, Issue 4 41-4, 1997, Pages

  Martin, Bradley J ^a   Lasley, Robert D ^a   Mentzer Jr , Robert M ^a  

^a UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

coronary venous adenosine; microdialysis; myocardial ischemia

Indexed keywords

2 [4 (2 CARBOXYETHYL)PHENETHYLAMINO]ADENOSINE 5' (N ETHYLCARBOXAMIDE); 8 (4 SULFOPHENYL)THEOPHYLLINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; ADENOSINE; DRAFLAZINE;

ACUTE HEART INFARCTION; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; HEART INFARCTION SIZE; HEART MUSCLE REPERFUSION; INTRAVENOUS DRUG ADMINISTRATION; MALE; MICRODIALYSIS; NONHUMAN; NUCLEOSIDE TRANSPORT; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; SWINE;

EID: 0031003369     PISSN: 03636135     EISSN: None     Source Type: Journal    
DOI: 10.1152/ajpheart.1997.272.4.h1857     Document Type: Article

References (21)

1. Belardinelli, L., J. Linden, and R. M. Berne. The cardiac effects of adenosine. Prog. Cardiovasc. Dis. 32: 73-97, 1989.
2. Beukers, M. W., C. J. M. Kerkhof, A. P. Ijzerman, and W. Soudijn. Nucleoside transport inhibition and platelet aggregation in human blood: R75231 and its enantiomers, draflazine and R88016. Eur. J. Pharmacol. 266: 57-62, 1994.
3. Böhm, M., C. Weinhold, R. H. G. Schwinger, J. Müller-Ehmsen, D. Böhm, H. Reichenspurner, B. Reichart, and E. Erdmann. Studies of the nucleoside transport inhibitor, draflazine, in the human myocardium. Br. J. Pharmacol. 112: 137-142, 1994.
4. Flameng, W., S. Sukehiro, T. Möllhoff, H. Van Belle, and P. Janssen. A new concept in long-term donor heart preservation: nucleoside transport inhibition. J. Heart Lung Transplant. 10: 990-998, 1991.
5. Galiñanes, M., Y. Qiu, H. Van Belle, and D. J. Hearse. Metabolic and functional effects of the nucleoside transport inhibitor R75231 in the ischemic and blood perfused rabbit heart. Cardiovasc. Res. 27: 90-95, 1993.
6. Goto, M., T. Miura, E. K. Iliodoromitis, E. L. O'Leary, R. Ishimoto, and D. M. Yellon. Adenosine infusion during early reperfusion failed to limit myocardial infarct size in a collateral deficient species. Cardiovasc. Res. 25: 943-949, 1991.
7. 1 receptor activation. J. Pharmacol. Exp. Ther. 268: 90-96, 1993.
8. Homeister, J. W., P. T. Hoff, D. D. Fletcher, and B. R. Lucchesi. Combined adenosine and lidocaine administration limits reperfusion injury. Circulation 82: 595-608, 1990.
9. Itoya, M., T. Miura, J. Sakamoto, K. Urabe, and O. Iimura. Nucleoside transport inhibitors enhance the infarct limiting effects of ischemic preconditioning. J. Cardiovasc. Pharmacol. 24: 846-852, 1994.
10. Kirkebøen, K. A., A. Ilebekk, T. Tønnessen, E. Leistad, P. A. Naess, G. Christensen, and G. Aksnes. Cardiac contractile function following repetitive brief ischemia: effects of nucleoside transport inhibition. Am. J. Physiol. 267 (Heart Circ. Physiol. 36): H57-H65, 1994.
11. Lasley, R. D., P. J. Konyn, J. O. Hegge, and R. M. Mentzer, Jr. Effects of ischemic and adenosine preconditioning on interstitial fluid adenosine and myocardial infarct size. Am. J. Physiol. 269 (Heart Circ. Physiol. 38): H1460-H1466, 1995.
12. 1 receptor mechanism. Am. J. Physiol. 263 (Heart Circ. Physiol. 32): H1460-H1465, 1992.
13. 1 receptor-mediated protection of the ischemic rat heart. J. Mol. Cell. Cardiol. 25: 815-821, 1993.
14. 1 receptor mediated protection of the globally ischemic rat heart. J. Mol. Cell Cardiol. 22: 39-47, 1990.
15. Masuda, M., A. Demeulemeester, C. Chang-Chun, M. Hendrikx, H. Van Belle, and W. Flameng. Cardioprotective effects of nucleoside transport inhibition in rabbits. Ann. Thorac. Surg. 52: 1300-1305, 1991.
16. Masuda, M., S. Sukehiro, T. Möllhoff, H. Van Belle, and W. Flameng. Effect of nucleoside transport inhibition on adenosine and hypoxanthine accumulation in the ischemic human myocardium. Arch. Int. Pharmacodyn. Ther. 322: 45-54, 1993.
17. Matherne, G. P., S. S. Berr, and J. P. Headrick. Integration of vascular, contractile, and metabolic responses to hypoxia: effects of maturation and adenosine. Am. J. Physiol. 270 (Regulatory Integrative Comp. Physiol. 39): R895-R905, 1996.
18. Matsuoka, H., K. J. Henrichs, and W. Schaper. Influence of dipyridamole on infarct size and on cardiac nucleotide content following coronary occlusion in the dog. Basic Res. Cardiol. 80: 682-692, 1985.
19. Maxwell, M. P., D. J. Hearse, and D. M. Yellon. Species variation in the coronary collateral circulation during regional myocardial ischemia: a critical determinant of the rate of evolution and extent of myocardial infarction. Cardiovasc. Res. 21: 737-746, 1987.
20. McClanahan, T. B., D. Ignasiak, B. J. Martin, T. E. Mertz, and K. P. Gallagher. Effect of adenosine deaminase inhibition with pentostatin on myocardial stunning in dogs. Basic Res. Cardiol. 90: 176-183, 1995.
21. Olaffsson, B., M. B. Forman, and D. W. Puett. Reduction of reperfusion injury in the canine preparation by intercoronary adenosine: importance of the endothelium and the no-reflow phenomenon. Circulation 76: 1135-1145, 1987.